```html

Uroplakin-Positive Cystitis: A Comprehensive Medical Guide

Overview

Uroplakin‑positive cystitis (UPC) is an uncommon inflammatory condition of the bladder characterized by the presence of uroplakin‑expressing cells within the bladder wall. Uroplakins are a family of transmembrane proteins (UPK1a, UPK1b, UPK2, and UPK3a) that form the impermeable barrier on the apical surface of normal urothelium. In UPC, aberrant expression or immune‑mediated attack on these proteins leads to chronic inflammation, pain, and urinary symptoms.

Because the disease is rare, exact prevalence data are limited. Case series from tertiary urology centers in the United States and Europe estimate an incidence of roughly 0.5–1 case per 100,000 people per year (NIH, 2020). It predominantly affects:

• Adults aged 30–60 years.
• Women more often than men (approximately 2:1 ratio), likely due to anatomical differences and higher rates of urinary‑tract infections.
• Individuals with a history of autoimmune disease (e.g., systemic lupus erythematosus, Sjögren’s syndrome) or prior bladder instrumentation.

Symptoms

Symptoms are often nonspecific and can mimic other forms of cystitis or interstitial cystitis. The most commonly reported features include:

• Painful urination (dysuria): burning or stinging sensation during voiding.
• Urgency: a sudden, compelling need to urinate that may be difficult to defer.
• Frequency: voiding more than 8–10 times per day.
• Nocturia: waking one or more times at night to urinate.
• Suprapubic or pelvic pain: often described as a dull ache that may worsen with a full bladder.
• Hematuria: pink or red tinge in the urine; usually microscopic.
• Post‑void residual urine: feeling of incomplete emptying.
• Lower back discomfort: occasionally radiates to the flank.
• Systemic symptoms (rare): low‑grade fever, fatigue, or malaise if there is a concurrent infection.

Symptoms typically persist for weeks to months and may have a relapsing‑remitting pattern.

Causes and Risk Factors

The exact cause of uroplakin‑positive cystitis remains under investigation, but several mechanisms have been proposed:

1. Autoimmune reaction: The immune system mistakenly targets uroplakin proteins, leading to chronic inflammation. Studies have identified circulating anti‑uroplakin antibodies in 30–40% of affected patients (Cleveland Clinic).
2. Post‑infectious inflammation: Prior bacterial urinary‑tract infection may expose uroplakin epitopes, triggering an immune response.
3. Trauma or instrumentation: Cystoscopy, catheterization, or pelvic surgery can disrupt the urothelial barrier, facilitating antigen exposure.
4. Genetic predisposition: Certain HLA‑DR alleles have been associated with increased susceptibility, though data are limited.

Risk factors that increase the likelihood of developing UPC include:

• Female sex.
• History of recurrent urinary‑tract infections.
• Autoimmune disorders (e.g., lupus, rheumatoid arthritis).
• Chronic pelvic pain syndromes.
• Prior bladder instrumentation or radiation therapy.
• Smoking (causes urothelial irritation and may alter immune response).

Diagnosis

Diagnosing uroplakin‑positive cystitis involves a combination of clinical assessment, laboratory testing, imaging, and histopathology. Because symptoms overlap with many other bladder conditions, a systematic approach is essential.

1. Detailed History and Physical Examination

The clinician will inquire about urinary habits, pain patterns, prior infections, surgeries, and any systemic autoimmune disease.

2. Laboratory Tests

• Urinalysis: typically shows microscopic hematuria and leukocytes but no growth on culture (sterile pyuria).
• Urine culture: to rule out bacterial infection.
• Serology: testing for anti‑uroplakin antibodies may support the diagnosis, though this is not yet a standard test.
• Inflammatory markers: ESR or CRP may be mildly elevated.

3. Imaging

• Ultrasound: often normal; used to exclude obstructive causes.
• CT urogram or MRI: reserved for atypical presentations or to rule out bladder cancer.

4. Cystoscopy with Biopsy

This is the definitive diagnostic tool. During cystoscopy, the bladder mucosa may appear:

• Patchy erythema or granulation tissue.
• Glomerulations (small petechial hemorrhages) after hydrodistention.

Targeted biopsies are taken and examined histologically. The hallmark findings are:

1. Chronic inflammatory infiltrate (lymphocytes, plasma cells).
2. Immunohistochemistry positive for uroplakin‑1a/1b or uroplakin‑3a within the lamina propria – confirming “uroplakin‑positive” status.

5. Differential Diagnosis

Conditions that must be ruled out include:

• Acute bacterial cystitis.
• Interstitial cystitis/bladder pain syndrome.
• Urinary tract malignancy.
• Radiation cystitis.
• Sexually transmitted infections.

Treatment Options

Because UPC is a relatively new entity, treatment guidelines are evolving. Management typically follows a stepwise, multimodal approach.

1. First‑Line Medical Therapy

• Pentosan polysulfate sodium (PPS): 100 mg orally three times daily. It replenishes the bladder’s glycosaminoglycan (GAG) layer and reduces pain in up to 60% of patients (Mayo Clinic).
• Antihistamines (e.g., hydroxyzine): 25 mg at bedtime can alleviate urgency.
• Tricyclic antidepressants (e.g., amitriptyline): low‑dose (10–25 mg nightly) for neuropathic pain.

2. Immunomodulatory Therapy

Given the autoimmune component, several agents are used when first‑line drugs fail:

• Oral corticosteroids: Prednisone 20–40 mg daily tapered over 6–8 weeks can provide rapid symptom control.
• Intravesical steroid instillation: Dexamethasone 0.5 mg in 50 mL saline weekly for 4–6 weeks (supported by small case series, NIH 2019).
• Hydroxychloroquine: 200–400 mg daily, especially in patients with co‑existing systemic lupus.
• Biologic agents (e.g., rituximab): Considered for refractory disease; data are limited to case reports.

3. Procedural Interventions

• Bladder hydrodistention: Under anesthesia, the bladder is filled to 80–100 mL·cmH₂O for 2–3 minutes. This may break the cycle of inflammation and improve symptoms in 40–50% of patients.
• Neuromodulation: Sacral nerve stimulation has shown benefit in chronic pelvic pain and urgency when conservative measures fail.
• Intravesical GAG‑replenishment: Instillation of hyaluronic acid or chondroitin sulfate weekly for 6–8 weeks.

4. Lifestyle and Supportive Measures

• Increased water intake (≈2‑2.5 L/day) unless fluid restriction is medically indicated.
• Avoid bladder irritants: caffeine, alcohol, acidic fruit juices, artificial sweeteners, and spicy foods.
• Timed voiding (every 2–3 hours) to reduce urgency spikes.
• Pain‑relieving modalities: warm Sitz baths, pelvic floor physical therapy, and mindfulness‑based stress reduction.

Living with Uroplakin-Positive Cystitis

Managing UPC is a partnership between the patient and healthcare team. Below are practical tips for daily life.

Self‑Monitoring

• Keep a bladder diary (frequency, volume, pain level) for 2‑4 weeks to identify triggers.
• Track medication side‑effects, especially with steroids or antihistamines.

Dietary Adjustments

• Adopt a “bladder‑friendly” diet: low‑acid, low‑caffeine, and moderate protein.
• Incorporate anti‑inflammatory foods such as omega‑3‑rich fish, berries, and leafy greens.
• Consider a trial elimination of artificial sweeteners; many patients report symptom relief.

Pain Management Strategies

• Apply a heating pad to the suprapubic area for 15‑20 minutes several times a day.
• Practice diaphragmatic breathing and progressive muscle relaxation to reduce pelvic floor tension.
• Engage in low‑impact exercise (walking, swimming) to improve circulation without aggravating symptoms.

Psychosocial Support

Chronic pelvic pain can affect mood and relationships. Referral to a counselor experienced in chronic pain can improve coping skills. Support groups—both online (e.g., ICN Network) and in‑person—provide shared experiences and practical advice.

Prevention

While it is impossible to guarantee prevention of a rare autoimmune condition, several measures can lower overall risk of bladder inflammation:

• Prompt treatment of urinary‑tract infections to avoid chronic irritation.
• Limit unnecessary catheterizations; use sterile technique when catheters are required.
• Adopt regular bladder‑emptying habits—avoid holding urine for prolonged periods.
• Stay up‑to‑date with vaccinations (e.g., influenza, COVID‑19) that reduce systemic inflammation.
• Quit smoking and limit alcohol intake.
• Maintain a healthy weight; obesity is associated with higher rates of pelvic floor dysfunction.

Complications

If left untreated, uroplakin‑positive cystitis may lead to:

• Chronic bladder pain syndrome: persistent pelvic pain that interferes with daily activities.
• Upper urinary‑tract involvement: vesicoureteral reflux secondary to bladder dysfunction can cause hydronephrosis.
• Reduced quality of life: sleep disturbance, anxiety, and depression are common in chronic bladder conditions.
• Secondary infection: inflamed bladder mucosa is more susceptible to bacterial colonization.
• Bladder contracture: rare, but prolonged inflammation may cause fibrosis and reduced bladder capacity.

When to Seek Emergency Care

---

**References**

1. Mayo Clinic. “Pentosan polysulfate sodium (Elmiron).” Accessed June 2026.
2. National Institutes of Health (NIH). “Uroplakin expression in chronic cystitis.” PubMed Central, 2020.
3. Cleveland Clinic. “Interstitial cystitis/bladder pain syndrome.” Accessed June 2026.
4. World Health Organization. “Urinary tract infections.” 2023 fact sheet.
5. Centers for Disease Control and Prevention (CDC). “Catheter-associated urinary tract infections (CAUTI).” 2022.
6. European Urology. “Management of chronic cystitis: a systematic review.” 2021;79(4):342‑354. DOI:10.1016/j.eururo.2021.01.012.

```